The European Medicines Agency (EMA) Validated Regulatory Application for Arpraziquantel, a Potential Treatment for Schistosomiasis in Preschool-Aged Children

Arpraziquantel is the first investigational drug in regulatory phase amongst the different projects supported by the GHIT (Global Health Innovative Technology) Fund. GHIT Fund has financed the clinical development of the Pediatric Praziquantel Consortium program for arpraziquantel since…